摘要
目的:比较紫杉醇脂质体与紫杉醇联合替吉奥一线治疗晚期胃癌的疗效和安全性。方法:将52例初治或复发的晚期胃癌患者分为紫杉醇脂质体联合替吉奥化疗组(n=27)和紫杉醇联合替吉奥化疗组(n=25),3周为一个化疗周期,每2个周期评价治疗效果和观察化疗毒副反应。结果:患者年龄32～80岁,中位年龄63岁,男性32例,女性20例。紫杉醇脂质体联合替吉奥治疗组和紫杉醇联合替吉奥组的有效率分别为44.4%和40%(P>0.05),疾病控制率分别为74.1%和68%(P>0.05);紫杉醇脂质体联合替吉奥组胃肠道反应和关节肌肉疼痛发生率较紫杉醇组降低(P<0.05)。结论:紫杉醇脂质体和紫杉醇联合替吉奥在晚期胃癌的治疗中疗效相当,但是紫杉醇脂质体的毒副反应更小,使用更方便,是晚期胃癌患者可选择的化疗药物之一。
Objective：To compare the efficacy and toxicity of paclitaxel liposome or paclitaxel in combination with S-1 as the first-line treatment of patients with advanced gastric cancer. Methods：A total of 52 patients with primary or recurrent advanced gastric cancer were divided into paclitaxel liposome plus S-1 group（ n = 27） and paclitaxel plus S-1 group（ n = 25）. One chemotherapeutic cycle consisted of three weeks. The efficacy and toxicity were evaluated every two cycles of chemotherapy. Results：The patients（32 males and 20 females） aged from 32 to 80 years with a median age of 63 years. The response rate was 44. 4% and 40%（ P 0. 05）,and the disease control rate was 74. 1% and 68%（ P〉 0. 05） for patients in the paclitaxel liposome plus S-1 group and paclitaxel plus S-1 group,respectively. However,the incidence of nausea,vomiting,and pain in the muscle and joint were significantly lower in patients in the paclitaxel liposome plus S-1 group than those in the paclitaxel plus S-1 group（ P 〈0. 05）. Conclusion：Paclitaxel liposome is as effective as paclitaxel in combination with S-1 in treating patients with advanced gastric cancer,yet paclitaxel liposome has less toxicity and easier administration,and may be as one of the chemotherapeutic agents for advanced gastric cancer.
作者
蔡娟
左学良
赵文英
叶晓兵
CAI Juan,ZUO Xueliang ,ZHAO Wenying , YE Xiaobing(Department of Ontology,The First Affiliated llospital of Wannan Medical College, Wuhu 241001, Chin)
出处
《皖南医学院学报》
CAS
2018年第3期247-250,共4页
Journal of Wannan Medical College
基金
皖南医学院中青年科研基金项目(WK2016F04)
关键词
晚期胃癌
紫杉醇脂质体
替吉奥
化疗
advanced gastric cancer
paclitaxel liposome
S-1
chemotherapy
